Investigational drug · Phase 2
YN001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "YN001"
First trial start
2023
Oct 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YN001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atherosclerosis
- Coronary Artery Disease
- Atherosclerotic Cardiovascular Disease
Approved drugs for the same conditions: Coronary artery disease and heart attack · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "YN001" as an intervention, largest first.
- A Phase 2b Clinical Trial of YN001 in Adults With Coronary AtherosclerosisPivotal-lookingRecruiting
Beijing Inno Medicine Co., Ltd.Industry
NCT07521007 · 456 participants (planned) · Start Jul 31, 2026 · Primary completion Jul 31, 2027
Drug: YN001/Placebo 40mg; YN001/Placebo 20mg and 1 more · For: Atherosclerosis; Coronary Artery Disease
Sites: Huntsville, Alabama; Covina, California; Lincoln, California · 56 sites in all
- YN001 in Healthy Subjects and Patients With Coronary AtherosclerosisPivotal-lookingCompleted
Beijing Inno Medicine Co., Ltd.Industry
NCT06048588 · 144 participants · Start Oct 8, 2023 · Primary completion Apr 27, 2025
Drug: YN001; Placebo for YN001 and 1 more · For: Atherosclerotic Cardiovascular Disease
Sites: Beijing, China; Wuhan, China; Changchun, China · 6 sites in all
Beijing Inno Medicine Co., Ltd.Industry
NCT05635084 · 64 participants · Start Dec 16, 2022 · Primary completion Aug 9, 2024
Drug: YN001; Placebo for YN001 · For: Cardiovascular Diseases
Sites: Melbourne, Australia
Beijing Inno Medicine Co., Ltd.Industry
NCT07311330 · 40 participants (planned) · Start Feb 4, 2026 · Primary completion Oct 2026
Drug: YN001 20mg Dose + 5% glucose injection · For: Atherosclerotic Cardiovascular Disease (ASCVD); Erectile Dysfunction
Sites: Beijing, China
Beijing Inno Medicine Co., Ltd.Industry
NCT07309042 · 24 participants · Start Dec 8, 2025 · Primary completion Mar 30, 2026
Drug: YN001, Rosuvastatin calcium Tablets; YN001, Rosuvastatin calcium Tablets and 1 more · For: Atherosclerotic Cardiovascular Diseases; Cerebrovascular Diseases
Sites: Changchun, China
Beijing Inno Medicine Co., Ltd.Industry
NCT07190885 · 24 participants (planned) · Start Nov 18, 2025 · Primary completion Sep 2026
Drug: YN001 · For: Healthy Volunteers
Sites: Adelaide, Australia
Beijing Inno Medicine Co., Ltd.Industry
NCT06700720 · 3 participants · Start Feb 25, 2026 · Primary completion Jul 22, 2026
Drug: Dose 1 YN001; Dose 2 YN001 and 1 more · For: Coronary Artery Disease; Coronary Atherosclerotic Disease
Sites: Canberra, Australia; Albury, Australia; Birtinya, Australia · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atherosclerosis
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- LepodisiranLY3819469Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- VERVE-102LY4636581Phase 21 trial
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.